Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day

Santhera Pharmaceuticals Holding AG / Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Liestal, Switzerland, Oxford, UK, Cambridge, Mass., 6 December 2017: Santhera Pharmaceuticals (SIX: SANN), Summit Therapeutics (NASDAQ: SMMT; AIM: SUMM), Catabasis Pharmaceuticals (NASDAQ: CATB) and Duchenne UK are pleased to announce a collaboration to host a Duchenne Muscular Dystrophy (DMD) Awareness Day today in London.

The half-day event will feature presentations by key opinion leaders representing clinical practitioners, industry professionals and the patient group Duchenne UK. Professor Dame Kay Davies FRS of the University of Oxford, Dr Rosaline Quinlivan MD of the National Hospital for Neurology and Neurosurgery and Professor Thomas Voit MD of Great Ormond Street Hospital and University College London will deliver keynote addresses focusing on the biology and aetiology of the disease, and the current treatment landscape.

The sponsoring companies will also present on their respective development programmes for new therapeutic options for DMD and the future outlook for patients.

Emily Crossley, Co-Founder and joint Chief Executive Officer of Duchenne UK, and Chair of the event, commented: "We are excited to be taking part in this comprehensive DMD awareness day. Duchenne UK is committed to working globally with industry to fund and accelerate drug development, and is delighted to be publicly collaborating with innovative companies such as Summit, Santhera and Catabasis. We are united in our mission to end Duchenne, and this event will raise much-needed awareness about this disease and highlight the growing pipeline of potentially life-changing treatments."  

A live audio webcast of the event will be available at the following link: https://edge.media-server.com/m6/p/nacwa6fn. A replay will be available on the supporting companies' websites the day after the event.

For further information of the event, please contact:
[e-mail]
[phone]

-  ENDS  -

About Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy is the most common fatal genetic disease diagnosed in childhood. Children born with DMD cannot produce the protein dystrophin which is vital for muscle strength and function. Muscle weakness starts in early childhood. Many use a wheelchair by around the age of 12. As deterioration continues it leads to paralysis and early death, often in their 20s. It almost exclusively affects boys. There is no treatment or cure. In the UK there are around 2,500 boys affected and around 300, 000 worldwide. It is classified as a rare disease.